Summary of patients' pretreatment characteristics
| No. of patients | 25 |
| Men | 9 |
| Women | 16 |
| Age, y | |
| Median | 46 |
| Range | 22-74 |
| Baseline platelet count, × 109/L | |
| Median | 13 |
| Range | 3-25 |
| Previous therapies | |
| Prednisone* | 25 |
| Intravenous immunoglobulin | 25 |
| High-dose dexamethasone | 11 |
| Splenectomy | 8 |
| Vincristine† | 5 |
| Pulse cyclophosphamide | 4 |
| Vitamin C | 2 |
| Anti-Rh globulin | 1 |
| ITP duration before rituximab treatment, mo | |
| Median | 22 |
| Range | 9-56 |
| Elevated PAIgG | 19/19 |
| Elevated ACA/LLA | 11 |
| ANA positive | 0 |
| Coombs tests positive | 0 |
| No. of patients | 25 |
| Men | 9 |
| Women | 16 |
| Age, y | |
| Median | 46 |
| Range | 22-74 |
| Baseline platelet count, × 109/L | |
| Median | 13 |
| Range | 3-25 |
| Previous therapies | |
| Prednisone* | 25 |
| Intravenous immunoglobulin | 25 |
| High-dose dexamethasone | 11 |
| Splenectomy | 8 |
| Vincristine† | 5 |
| Pulse cyclophosphamide | 4 |
| Vitamin C | 2 |
| Anti-Rh globulin | 1 |
| ITP duration before rituximab treatment, mo | |
| Median | 22 |
| Range | 9-56 |
| Elevated PAIgG | 19/19 |
| Elevated ACA/LLA | 11 |
| ANA positive | 0 |
| Coombs tests positive | 0 |